Canton Hathaway »

Protagonist Therapeutics shares owned by Canton Hathaway

Quarter-by-quarter ownership of Protagonist Therapeutics (PTGX) shares owned by Canton Hathaway from 13F filings

Historical chart of Canton Hathaway investment in Protagonist Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Protagonist Therapeutics held by Canton Hathaway consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Protagonist Therapeutics by Canton Hathaway

Quarter filed Position value Share count Share price at filing
2025-12-31 $87k 1.0k 87.34

More positions owned by Canton Hathaway

Berkshire Hathaway (BRK.A)
Vanguard 500 ETF Etf (VOO)
Spdr Gold Tr Gold Etf (GLD)
Alphabet Inc Class C cs (GOOG)
Microsoft Corporation (MSFT)
Ishares Msci Eafe Etf Etf (EFA)
iShares Silver Trust Etf (SLV)
Berkshire Hathaway (BRK.B)
Amazon (AMZN)
Qxo (QXO)
Apple (AAPL)
Bloom Energy Corp (BE)
Industrial Select SPDR ETF Etf (XLI)
NVIDIA Corporation (NVDA)
JPMorgan Chase & Co. (JPM)

View all positions for Canton Hathaway

Top funds holding Protagonist Therapeutics

BlackRock
Farallon Capital Management
Vanguard Group
Rtw Investments
State Street Corporation
UBS Group
BVF
Johnson & Johnson
Wellington Management Company
Invesco
Geode Capital Management
Woodline Partners
Driehaus Capital Management
Henderson Group
ADAR1 Capital Management

View all funds holding Protagonist Therapeutics